2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Pain, Postoperative
9
Pain
5
Neuralgia
5
Breast Neoplasms
5
Agnosia
4
Neoplasms
3
Head and Neck Neoplasms
2
Chronic Pain
2
Visceral Pain
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Seizures
1
Pinealoma
1
Persistent Postoperative Pain
1
Pancreatic Neoplasms
1
Pain, Intractable
1
Oropharyngeal Neoplasms
1
Oligodendroglioma
1
Obesity
1
Neuroectodermal Tumors, Primitive
1
Myotoxicity
1
Mouth Neoplasms
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Follicular
1
Lymphoma
1
Liver Neoplasms
1
Leiomyoma
1
Inflammation
1
Hot Flashes
1
Interventions
Exercise
5
Vitamin D
3
Resistance Training
3
Omeprazole
3
Etanercept
3
Dexmedetomidine
3
Ascorbic Acid
3
salicylsalicylic acid
2
palbociclib
2
epigallocatechin gallate
2
XENP 1595
2
Tea
2
Tablets
2
Surgical Procedures, Operative
2
Sufentanil
2
Spironolactone
2
Probiotics
2
Pioglitazone
2
Oxycodone
2
Nutrition Assessment
2
Morphine
2
Metformin
2
Ketorolac
2
Infliximab
2
Ibuprofen
2
Fish Oils
2
Endurance Training
2
Colchicine
2
Blood Specimen Collection
2
Aspirin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammation
×
Pregabalin
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled